 |
 |
Amorcyte is a biotechnology company developing cell therapy products to treat cardiovascular disease.
Its lead product AMR-001, for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed Phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. This is the first prospective stem cell trial in AMI ever conducted that has established a statistically significant relationship between dose and effect.
Amorcyte has partnered with Progenitor Cell Therapy, a leading provider of clinical, manufacturing and other services for the cell therapy industry, to provide Amorcyte with a pharmaceutical grade cGMP manufactured product that can be distributed commercially.
Click here, to download a fact sheet on Amorcyte and AMR-001. |
|
|
|
|
|
|
|
|
 |
|
AMORCYTE STEM CELL THERAPY DEMONSTRATES CLINICALLY SIGNIFICANT REPERFUSION IN SEVERE HEART ATTACK PATIENTS
American Heart Journal Publication Establishes Achievement of Threshold Dose
Allendale, NJ, December 21, 2010
AMORCYTE REPORTS PHASE I RESULTS OF AMR-001 TO IMPROVE RECOVERY FROM SEVERE HEART ATTACK AT ACC ANNUAL SCIENTIFIC SESSION
First Stem Cell Trial to Show Dose-related Significant Improvement in Perfusion
Orlando, Fla, March 30, 2009
After Heart Attack, Bone Marrow Stem Cells Increase Blood Flow Within Heart
Orlando, Fla, March 30, 2009
AMORCYTE COMPLETES PHASE I TRIAL OF STEM CELL THERAPY FOR ACUTE MYOCARDIAL INFARCTION
(Amorcyte) announced today the completion of the phase I clinical trial of its lead product, AMR-001.
HACKENSACK, New Jersey - (April 1, 2008)
AMORCYTE CARDIAC CELL THERAPY TRIAL COMPLETES SECOND OF FOUR PHASES
Stem cell therapy trial picks up pace with three sites now accruing patients
Hackensack, New Jersey - May 8, 2007
|
|
